(Q34396079)

English

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

ORCID Public Data File 2021

Francesco Forconi

1 reference

ORCID Public Data File 2021

Elisabetta Abruzzese

1 reference

ORCID Public Data File 2021

author name string

M Bocchia

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

S Gentili

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

E Abruzzese

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A Fanelli

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F Iuliano

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A Tabilio

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

M Amabile

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F Forconi

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A Gozzetti

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

D Raspadori

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

S Amadori

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F Lauria

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

365

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

9460

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

657-662

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917945-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(05)17945-8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34396079&oldid=1584554704"